Abstract
Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Current Respiratory Medicine Reviews
Title: Mesothelioma - Epidemiology and Management
Volume: 7 Issue: 5
Author(s): Patricia Tai, Edward Yu, Avi Assouline and Kurian Joseph
Affiliation:
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Abstract: Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Export Options
About this article
Cite this article as:
Tai Patricia, Yu Edward, Assouline Avi and Joseph Kurian, Mesothelioma - Epidemiology and Management, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189731
DOI https://dx.doi.org/10.2174/157339811797189731 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiogenesis and Angiogenic Inhibitors in Non Small Cell Lung Cancer
Current Angiogenesis (Discontinued) Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Current Drug Targets Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes
Current Pharmaceutical Design Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Current Pharmaceutical Design Neuroprotective Effects of Melanocortins in CNS Injury
Current Pharmaceutical Design Non-invasive Biodiversified Sensors: A Modernized Screening Technology for Cancer
Current Pharmaceutical Design Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Investigating the In Vivo Expression Patterns of miR-7 microRNA Family Members in the Adult Mouse Brain
MicroRNA Molecular Targets in Malignant Pleural Mesothelioma Treatment
Current Drug Targets Mapping the Technological Knowledge Landscape: The Case of Epigenetics
Recent Patents on Anti-Cancer Drug Discovery Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets